Genomic analysis of early-stage lung cancer reveals a role for TP53 mutations in distant metastasis

Autor: Debra Van Egeren, Khushi Kohli, Jeremy L. Warner, Philippe L. Bedard, Gregory Riely, Eva Lepisto, Deborah Schrag, Michele LeNoue-Newton, Paul Catalano, Kenneth L. Kehl, Franziska Michor, for the AACR Project GENIE Consortium represented by Shawn Sweeney

Publikováno v: Scientific Reports, Vol 12, Iss 1, Pp 1-6 (2022)

Abstract Patients with non-small cell lung cancer (NSCLC) who have distant metastases have a poor prognosis. To determine which genomic factors of the primary tumor are associated with metastasis, we analyzed data from 759 patients originally diagnos

Externí odkaz: https://doaj.org/article/38d145c0f30540fe966086128a46be62

Supplementary Data from Analysis of Genetic Variants in Never-Smokers with Lung Cancer Facilitated by an Internet-Based Blood Collection Protocol: A Preliminary Report

Autor: William Pao, Keitaro Matsuo, Robert J. Klein, Vincent Miller, Gregory Riely, Mark G. Kris, Agnes Viale, Marc Ladanyi, Khedoudja Nafa, Yasushi Yatabe, Irene Orlow, Megan Harlan, Mark Robson, Rekha Reddy, Christopher G. Azzoli, Emil Lou, Nicolas Girard

Supplementary Data from Analysis of Genetic Variants in Never-Smokers with Lung Cancer Facilitated by an Internet-Based Blood Collection Protocol: A Preliminary Report

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::276fbda8244144307baf35f1a985b8b2
https://doi.org/10.1158/1078-0432.22442609

A Scalable Quality Assurance Process for Curating Oncology Electronic Health Records: The Project GENIE Biopharma Collaborative Approach

Autor: Jessica A, Lavery, Eva M, Lepisto, Samantha, Brown, Hira, Rizvi, Caroline, McCarthy, Michele, LeNoue-Newton, Celeste, Yu, Jasme, Lee, Xindi, Guo, Thomas, Yu, Julia, Rudolph, Shawn, Sweeney, Ben Ho, Park, Jeremy L, Warner, Philippe L, Bedard, Gregory, Riely, Deborah, Schrag, Katherine S, Panageas

Publikováno v: JCO clinical cancer informatics. 6

PURPOSE The American Association for Cancer Research Project Genomics Evidence Neoplasia Information Exchange Biopharma Collaborative is a multi-institution effort to build a pan-cancer repository of genomic and clinical data curated from the electro

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::5f296784c1f9a3dc9af55595e5193186
https://pubmed.ncbi.nlm.nih.gov/35192403

Nazartinib for treatment-naive EGFR-mutant non-small cell lung cancer: Results of a phase 2, single-arm, open-label study

Autor: Daniel S.W. Tan, Sang-We Kim, Santiago Ponce Aix, Lecia V. Sequist, Egbert F. Smit, James C.H. Yang, Toyoaki Hida, Ryo Toyozawa, Enriqueta Felip, Juergen Wolf, Christian Grohé, Natasha B. Leighl, Gregory Riely, Xiaoming Cui, Mike Zou, Samson Ghebremariam, Leslie O'Sullivan-Djentuh, Riccardo Belli, Monica Giovannini, Dong-Wan Kim

Publikováno v: Tan, D S W, Kim, S-W, Ponce Aix, S, Sequist, L V, Smit, E F, Yang, J C H, Hida, T, Toyozawa, R, Felip, E, Wolf, J, Grohé, C, Leighl, N B, Riely, G, Cui, X, Zou, M, Ghebremariam, S, O'Sullivan-Djentuh, L, Belli, R, Giovannini, M & Kim, D-W 2022, ' Nazartinib for treatment-naive EGFR-mutant non−small cell lung cancer : Results of a phase 2, single-arm, open-label study ', European Journal of Cancer, vol. 172, pp. 276-286 . https://doi.org/10.1016/j.ejca.2022.05.023
European Journal of Cancer, 172, 276-286. ELSEVIER SCI LTD
European Journal of Cancer, 172, 276-286. Pergamon

Introduction: Nazartinib, a novel third-generation EGFR-tyrosine kinase inhibitor, previously demonstrated antitumor activity and manageable safety in patients with EGFR-mutant advanced non−small cell lung cancer (NSCLC) who received ≤ 3 prior li

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::c3d408a2962f460fc04239dba68d9e66
https://pubmed.ncbi.nlm.nih.gov/35810553

Efficacy of Vemurafenib in Patients With Non-Small-Cell Lung Cancer With

Autor: Vivek, Subbiah, Radj, Gervais, Gregory, Riely, Antoine, Hollebecque, Jean-Yves, Blay, Enriqueta, Felip, Martin, Schuler, Anthony, Gonçalves, Antonio, Italiano, Vicki, Keedy, Ian, Chau, Igor, Puzanov, Noopur S, Raje, Funda, Meric-Bernstam, Martina, Makrutzki, Todd, Riehl, Bethany, Pitcher, Jose, Baselga, David M, Hyman

Publikováno v: JCO Precision Oncology

PURPOSE To study whether BRAF V600 mutations in non–small-cell lung cancer (NSCLC) may indicate sensitivity to the BRAF inhibitor vemurafenib, we included a cohort of patients with NSCLC in the vemurafenib basket (VE-BASKET) study. On the basis of

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=pmid________::7d8cb792e0c1d0450c316a2936f68ccb
https://pubmed.ncbi.nlm.nih.gov/32914022